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Abstract 
Fibromyalgia (also known as fibromyalgia syndrome, or FMS) is a condition which 
causes its victims to suffer a wide range of symptoms, most notably chronic 
musculoskeletal pain. Although the causes of fibromyalgia remain unknown, recent 
advances help elucidate the underlying pathophysiologies of this condition, and show that 
it is likely not a musculoskeletal condition, but rather a pathoneurological condition. 
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Fibromyalgia Syndrome 
A Pathoneurological Basis of Disease 
Introduction 
   One condition which has continued to increase in the public’s awareness is 
fibromyalgia syndrome (FMS), better known as fibromyalgia. Although many people 
have heard of fibromyalgia, however, few have a good understanding of this mysterious, 
painful condition. Even now, fibromyalgia’s origins remain unknown, and this has 
historically led researchers to label it a psychosomatic condition. However, as research 
has progressed, new data has evolved to validate the claims of those suffering from 
fibromyalgia, indicating this condition merits further research in order to develop a cure. 
 While fibromyalgia was studied as early as the 1600s, as muscular rheumatism, 
and later in the 1800s, as hysterical paroxysm, its definite symptoms appear to have been 
first diagnosed in 1904, when it was called fibrositis. At that time, fibrositis was just a 
general word for pain that seemed to derive from muscle fibers due to inflammation. 
Much later, the name evolved from fibrositis to fibromyalgia, as the understanding of the 
condition began to increase, and researchers realized that it was not an inflammatory 
disease. In the 1970s, a modern understanding of this condition began to take shape, 
when it was described simply as pain in many locations with multiple pressure points, or 
highly localized areas of increased sensitivity to pressure. During this time period, 
medical researchers assumed that this was an autoimmune disease, and tried to identify 
its pathophysiology. However, they failed to find anything wrong with the autoimmune 
system (even during the 1990s). At this point, many researchers began to believe that 
fibromyalgia was in fact a psychosomatic condition. 
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In 1981, studies demonstrated that there was a list of eighteen consistent pressure 
points in addition to a common set of symptoms. Although many of the symptoms tended 
to be subjective (namely, the severity of pain experienced by the patient), the list 
supported the belief that fibromyalgia was a specific condition, and not simply a figment 
of the patient’s imagination. This belief was reinforced in the late 1980s, when 
researchers noted that serotonergic drugs were consistently effective, because they helped 
to reduce pain (as measured with questionnaires). It wasn’t until 1990, however, that the 
American College of Rheumatology (or the ACR) established the first diagnostic criteria. 
Since then, as new technology has developed, researchers have identified specific parts of 
the body (in particular, the central nervous system) which appear to be affected among 
patients suffering from fibromyalgia. This has given greater credence to the actuality of 
the disease (Inanici & Yunus, 2004).  
Incidence 
It has previously been reported that women are seven times more likely than men 
to develop fibromyalgia. However, studies have indicated that while 0.068 percent of 
men are likely to develop FMS, only 0.113 percent of women develop it (Weir et al., 
2006). This means that women are only 1.6 times more likely to develop FMS than men. 
Overall, it is estimated that there is a prevalence of about two percent of the American 
population (Seidel & Muller, 2011) 
Symptoms 
 Part of what makes fibromyalgia such a controversial disease (and why many 
medical professionals over the years have labeled it psychosomatic) is its diverse and 
complex list of symptoms. As a syndrome, fibromyalgia has many possible symptoms 
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which could indicate FMS, and most occur independently of each other. In addition, these 
symptoms often occur with other conditions, such as arthritis or chronic fatigue 
syndrome. Complicating the matter, these symptoms often come and go between periods 
of intense expression and less severe expression. For example, a patient may experience a 
higher level of severe pain for a time, only to return to experiencing milder pain. Because 
of this diversity, no two people with fibromyalgia experience exactly the same symptoms 
(and especially not for the same durations of various intensities). Chronic pain remains 
the most underlying consistent symptom of all expressions of fibromyalgia and is often 
musculoskeletal in nature, affecting muscles, fasciae and joints. However, fibromyalgia 
syndrome is often accompanied by a host of other symptoms that frequently affect 
various parts of the body.  
Pain 
 Chronic pain is the most prevalent symptom of fibromyalgia. However, this pain 
rarely remains in one location, but spreads widely throughout the body, and often moves 
to different locations. Patients often report experiencing intense pain in the arm, for 
example, but later, in the lower back. Apart from this chronic pain, those suffering from 
fibromyalgia also experience high levels of pain after even mild trauma. In fact, a bump 
or a squeeze, which may cause the average person mild discomfort for a few seconds, 
tends to hurt those with fibromyalgia for up to a few minutes. A study conducted in 2004 
demonstrated via MRIs that those with FMS do in fact feel more pain from stimuli than 
healthy controls (Giesecke et al., 2004). In addition to the chronic pain and the low pain 
tolerance, those with fibromyalgia frequently have a host of pressure points throughout 
the body which are especially sensitive to touch, and where pain often congregates 
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(Blumenstiel et al., 2011; Wilbarger & Cook, 2011). It is also interesting to note that 
among patients with FMS, EEGs (or electroencephalograms) demonstrate a quicker 
response to pain than in healthy controls. EEGs involve attaching electrodes to a patient’s 
head in order to measure brain activity during various stimuli. In a study performed in 
2000, EEGs of healthy controls were compared to those of FMS patients during a cold 
pressor test, where the test subject immerses a hand into ice water for a definite period of 
time. Those with FMS consistently reported the pain as “intolerable” sooner than healthy 
test subjects, and the EEGs indicated a higher level of brain activity in a shorter amount 
of time, thereby indicating that the FMS patients felt pain sooner in a quantitative manner 
(Stevens, Batra, Kotter, Bartels, & Schwarz, 2000). 
Confusion 
 Apart from the pain, another characteristic of fibromyalgia is something often 
referred to as “fibro fog.” In high-stress situations, such as events with lots of background 
noise or flashing lights, many of those who suffer from fibromyalgia begin to lose mental 
acuity. This can manifest itself in two forms. In severe cases, it can occur as mild 
memory loss (wherein patients have difficulty recalling information, such as common 
words for objects). However, it can also be seen as slow or “cloudy” thinking. This 
includes a drawn out decision making process as well as poor choices. To someone 
viewing a patient, the most notable characteristic of fibro fog is slow reflexes.  Many 
patients who have experienced fibro fog describe it as a “zoned out” feeling, and a certain 
inability to do anything about it, much like when the average person is severely sleep 
deprived.  
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Stress 
 Another primary characteristic of FMS is high levels of stress. While some people 
speculate that stress causes the onset of fibromyalgia, others consider stress a symptom. 
In reality, this aspect of fibromyalgia is a lot more controversial, since some people 
simply hide stress better than others, or apply different standards to describe a stressful 
situation. Regardless, stress produces many effects, one of which seems to be sudden 
changes in emotion. Those with fibromyalgia frequently suffer from a significantly 
greater amount of anxiety (measured with surveys and questionnaires) than an average 
healthy individual, and quickly begin to worry about things that could go wrong, 
especially in stressful situations.  
Insomnia 
 Many FMS patients report difficulty sleeping at night. Again, many researchers 
disagree as to whether this is due to pain or other conditions, or whether this causes the 
other symptoms. Regardless, sleep deficiency decidedly alters the lifestyle of 
fibromyalgia patients. First, it exacerbates the other symptoms (which are often 
aggravated among healthy individuals who don’t get enough sleep). Second, it adds to the 
psychological factor among FMS patients, who often report having anxious thoughts as 
they lie awake at night.  
Depression 
 One of the more crippling aspects of FMS is the emotional toll it takes on its 
victims. This most frequently occurs as depression. While researchers have observed 
physiological reasons for this depression, many fibromyalgia patients also express 
discouragement at the prospect of living an entire life with the symptoms (especially the 
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pain) of their illness. As with the other associated symptoms, however, depression tends 
to oscillate in its severity. 
Associated Conditions 
 In addition to the characterizing symptoms already mentioned, another factor in 
fibromyalgia is that it is associated with many other diseases. Most of these associated 
conditions are stress-related, which means that they may share a common cause with 
FMS. 
One of the most commonly associated conditions is known as IBS, or irritable 
bowel syndrome. IBS demonstrates a prevalence ranging anywhere from 30-70% among 
FMS patients, as opposed to the typical 10-20% occurrence among healthy individuals 
(Sperber & Dekel, 2010). Characterized by abdominal pain, cramping, and 
inconsistencies in bowel movements, IBS is similar to what the average person 
experiences during times of high anxiety, such as before public speaking. In fact, IBS 
may be more related to stress than anything else. A study conducted in 2008 
demonstrates a correlation between psychosocial factors (including anxiety and sleep 
problems) and presentations of IBS, increasing the probability that IBS and FMS could 
share a common stress related etiology (Nicholl et al., 2008). 
Another associated condition is GERD, or gastrointestinal esophageal reflux 
disease, which occurs when stomach acids “leak up” into the esophagus. This is most 
commonly experienced as heartburn, and causes sleep disturbances due to pain. 
Another commonly associated condition is arthritis. Known for causing joint 
pains, arthritis manifests itself very similarly to fibromyalgia. This is one reason why 
fibromyalgia is so difficult to detect, since many other conditions explain, in part, FMS’s 
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symptoms. Arthritis adds to the pain that FMS patients feel in their joints, and can even 
cause joint degeneration. 
Fibromyalgia also includes a host of other associated conditions, including 
Crohn’s disease, chronic fatigue syndrome, hypothyroidism, and carpal tunnel syndrome. 
However, due to the length of the list, patients with FMS typically have just a few of the 
associated conditions. 
Diagnosis  
Given fibromyalgia’s tendencies to look like other conditions, it is a very difficult 
condition to diagnose. Not only does fibromyalgia vary in how it manifests pain, but pain 
itself is also incredibly subjective, varying from person to person according to his or her 
pain tolerance. In reality, most doctors have accepted that fibromaylgia must be 
diagnosed by a process of elimination. However, there are also two other positive tests 
commonly used in its diagnosis. 
Diagnosis Via the Elimination Process 
 As for the elimination process, some of the most commonly performed tests are 
blood tests, including rheumatoid factor (RF) to test for rheumatoid arthritis among other 
things, or a complete blood count (CBC) to rule out other potential diseases, such as 
lupus, anemia, or polymyalgia rheumatica. Additional tests, such as erythrocyte 
sedimentation rate (ESR), may also be ordered to confirm the CBC’s negative results. In 
addition, there are blood tests searching for specific chemicals or proteins, such as 
checking TSH levels in the blood to rule out hypothyroidism. Negative results from these 
tests help to support a diagnosis from two other sets of inconclusive positive test results.  
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ACR Test 
 The first positive test created, called the ACR test (American College of 
Rheumatology test, developed in 1990), simply tests the number of pain-inducing 
pressure points in a patient. In total, there are eighteen pressure points from which to 
choose, as seen in Figure I. A doctor uses discernment in how much pressure to apply 
(though always less than nine pounds of force), and if a patient reports significant pain 
with mild pressure in at least eleven of the eighteen points, the test is positive for 
fibromyalgia. While the specific cause for these painful pressure points remains 
unknown, it is clear that they are frequently in similar, localized areas on the body. 
Modern medicine has deemed the ACR test insufficient to diagnose FMS, however, and 
this has led caregivers to develop other tests to assist in making a diagnosis. 
WPI/SS 
 More recently, another method has been developed which includes two facets. 
First, there is a widespread pain index (WPI). For this, the patient chooses which parts of 
his or her body have hurt within the past week from a list of nineteen body parts. For 
each part listed, the patient receives a score of one, producing a total score ranging from 
zero to nineteen. Secondly, there is a symptom severity score (SS score). In this scoring 
system, the patient ranks the severity from zero to three in four different categories, 
including fatigue, waking up unrefreshed, cognitive symptoms (such as anxiety or fibro 
fog), and a fourth area, somatic symptoms in general. For the first three, a simple score is 
given between zero and three. For the fourth, the patient chooses from among forty-one 
general somatic symptoms, and tallies“points” from that (0-10 symptoms is roughly equal 
to one point, 11-24 symptoms is about equal to two, and 25+ is approximately equal to 
FIBROMYALGIA SYNDROME  12 
three). 
 
 
Figure I: Pressure Points in Fibromyalgia Syndrome. As can be seen, there are 
eighteen pressure points listed. A patient with at least eleven of these is diagnosed as 
positive for fibromyalgia according to the ACR test (Garcia, E., Godoy-Izquierdo, D., 
Godoy, J.F., Perez, M. & Lopez-Chicheri, I, 2007). 
 
 Given the scores from the WPI test and the SS score, a three part criteria was 
developed. First, the symptoms must have persisted for at least three months. Second, 
there must be no other disease that can explain the symptoms (which is why the negative 
tests must be run). Third, either the WPI score must be greater than or equal to seven with 
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an SS score greater than or equal to five, or the WPI score must be between three and six 
with an SS score greater than eight (Wolfe & Hauser, 2011). 
 The advantage offered by the second method (that is, the WPI/SS) is that it is 
more consistent than the ACR test. In addition to the ACR test’s fluctuations based on 
how hard a doctor applies pressure (which is very difficult to replicate uniformly), many 
doctors simply cannot pinpoint the pressure points. Based on the difficulties associated 
with performing the ACR test, it is now recommended that caregivers use both the ACR 
test and the WPI/SS score tests (both in conjunction with the process of elimination), but 
that they rely more heavily on the latter. 
Pathophysiology 
The causes of fibromyalgia have yet to be understood from a biochemical or 
molecular biological perspective. Many researchers have speculated about what actually 
causes the body to respond to stress the way bodies of FMS patients do, but the answer 
has so far eluded them. However, recent discoveries describing the pathophysiologies of 
FMS patients may lead to a better understanding of this condition. 
Decaying Gray Matter  
Interestingly, research has demonstrated that those suffering from fibromyalgia seem to 
lose more gray matter in the brain than the average person. Researchers in Quebec, 
Canada have used voxel based morphometric analysis of gray matter in magnetic 
resonance images to compare brains from FMS patients with those of healthy individuals 
as controls. Morphometric analysis simply measures the volume and shape of the organ 
of interest and its subparts. Voxel based morphometry uses scanning techniques (in this 
case, MRI) as well as statistics to determine the size of the organ of interest. The 
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researchers found that patients with fibromyalgia lost on average about nine and a half 
times as much gray matter per year compared to a typically healthy individual. From a 
neurological perspective, this leads to the appearance of aging at a faster rate with regards 
to the brain, with about a three times greater age-associated decrease in gray matter. 
However, researchers haven’t yet discovered the cause for this loss in gray matter 
(Kuchinad et al., 2007; Robinson, Craggs, Price, Perlstein, & Staud, 2011). Regardless, 
the correlation between decreasing gray matter volume and chronic pain has been 
observed in more instances than just those of patients suffering from FMS (Wood, 2010). 
In fact, the decrease in brain matter has also been observed in patients who are diagnosed 
with bipolar I disorder (Li et al., 2011).  
Regions of the brain which tend to experience the greatest impact are the 
cingulate, insular and medial frontal cortices, and the parahippocampal gyri (Kuchinad, et 
al., 2007).  The cingulate, a part of the limbic system, plays a key role in the formation of 
emotions and may help explain the difficulty some FMS patients have controlling their 
emotions. In addition, it is a major pain regulator of the brain, and an alteration in its 
function could explain the low pain tolerance of FMS patients. The insular cortex takes 
part in a wide range of functions, including social emotions, “emotional tasks with 
cognitive demand” and pain management (Phan, Wager, Taylor, & Liberzon, 2002; 
Robinson, et al., 2011). Interestingly, the insular cortex also plays a role in irritable bowel 
syndrome (IBS), a major associated symptom of fibromyalgia, by altering pain 
perception of the rectum (Song et al., 2006). The frontal cortex is important in general 
cognitive processes, including motor responses and social responses. Multiple studies 
indicate that there is a strong association between altered frontal cortex function and 
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several psychiatric conditions including depression, schizophrenia, and obsessive-
compulsive disorder (Jaracz & Rybakowski, 2005; Tamminga & Buchsbaum, 2004). As 
for the parahippocampal region, research indicates that it is involved with topographical 
learning and that in some cases, damage can be associated with schizophrenia (Aguirre, 
Detre, Alsop, & D’Esposito, 1996; McDonald et al., 2000). However, this doesn’t seem 
to match any of the commonly reported symptoms of FMS, which may indicate other 
areas of the brain also assist in topographical learning.  
Decreased Pain Inhibition 
 Of all the pathophysiologies associated with fibromyalgia, one of the most keenly 
observed is a decrease in pain inhibition. Using various techniques (such as thermal 
scanning or MRI), researchers have observed brain activity during mild physical trauma 
in patients with FMS compared to healthy individuals, and have found an irrefutable 
increase in pain sensitivity (Normand et al., 2011). Again, researchers have yet to 
discover why FMS patients are unable to inhibit pain as efficiently as healthy individuals, 
and whether the condition stems from the peripheral nervous system, the spinal cord, or 
the brain. However, one study has shown, via functional MRI scans, that healthy 
individuals have significantly higher levels of connectivity in the amygdala, 
hippocampus, brainstem, and especially the rostral anterior cingulate cortex (Jensen et al., 
2012). Again, since these play significant roles in pain moderation, it seems plausible that 
the telltale FMS symptom of chronic pain may stem from a pathoneurological source. 
Chemical Imbalances 
 Serotonin. One of the best known neurotransmitters, serotonin (also called 5-HT 
for 5-hydroxytryptamine), seems to be involved in FMS. Multiple studies have suggested 
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that serotonin levels in the brain may be lower than normal among patients with 
fibromyalgia (Neeck, 2000). Since serotonin is the “feel good” neurotransmitter, it is 
fairly obvious that a decrease in its concentration could cause some of the symptoms of 
FMS. However, there is some debate among researchers as to what causes the low 
serotonin levels in FMS patients. A study done in 1999 seemed to indicate that there may 
be a correlation between FMS and 5-HTT, a serotonin transporter which was previously 
assumed to be responsible for the low serotonin levels (Offenbaecher et al., 1999). There 
are two primary types of the degenerate repeat polymorphic region of the gene which 
encodes serotonin, 5-HTTLPR (serotonin-transporter-linked polymorphic region), a long 
allele (L) and a short (S), and the study seemed to indicate the those with FMS were 
predisposed to having an S/S genotype, which other studies have demonstrated leads to a 
susceptibility to depression. A more recent study, however, suggests that there is no 
significant correlation between 5-HTT and FMS. This study found that among one 
hundred and twenty volunteers (half were normal healthy candidates and the other half 
had been diagnosed with FMS), the percentages of the genotypic variations were similar 
in both the FMS patients and the healthy candidates (Gursoy, 2002). Another study, 
performed in 2012, also indicates that there is little to no correlation between 
fibromyalgia and 5-HTT, but does reveal a strong association between FMS and the 
expression of a serotonin receptor, 5-HT2A, and specifically its T102C polymorphism 
(Y. H. Lee, Choi, Ji, & Song, 2012).  Interestingly, many other studies have found that an 
over expression of this specific polymorphism is often associated with suicidal tendencies 
(Du, Faludi, Palkovits, Bakish, & Hrdina, 2001; Vaquero-Lorenzo et al., 2008). 
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 Brain-derived neurotrophic factor. A second factor which may play a 
significant role in fibromyalgia is known as brain-derived neurotrophic factor, or BDNF. 
BDNF has previously been demonstrated to play a role in depression and anxiety (Lang 
et al., 2005; Montag, Reuter, Newport, Elger, & Weber, 2008). To study this relationship, 
serum levels of BDNF were measured in both healthy controls and FMS patients during 
periods with varying intensities of depression, measured with the NEO-Five Factor 
Inventory (a personality test to measure, among other things, neuroticism, which is the 
tendency towards anxiety), and the State-Trait Anxiety Inventory, also measuring 
anxiety. Interestingly, there seemed to be a correlation between decreased levels of serum 
BDNF and the severity of the patients’ depression (Lang, et al., 2005; Nugraha, Korallus, 
& Gutenbrunner, 2013). However, a separate study demonstrated that disrupting the 
signaling pathways involving BDNF did not induce depression, but did decrease 
responses to antidepressants (measured again with questionnaires). This suggests that a 
shortage of BDNF may not be the sole cause of depression, but that increasing BDNF 
concentrations may be a target for antidepressant drugs, in order that other 
antidepressants can be more effective. (Martinowich, Manji, & Lu, 2007).  
Treatment 
Sadly, once a diagnosis has been given, many individuals begin to experience 
despair, since there are currently no cures for fibromyalgia (given that researchers are still 
unsure what causes it). At best, various medications and treatments are administered in 
order to reduce the severity of symptoms, but that is all that doctors can currently do, as 
is often the case with diseases. However, the field of palliative care (which simply 
reduces the severity of the symptoms) for FMS patients offers a wide range of treatment 
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plans which seem to significantly reduce suffering, including: medications, lifestyle 
changes, and alternative medicinal treatments 
Medications 
 Obviously, since the cause of fibromyalgia remains unknown, there is a limit to 
the effectiveness of medications. As is the case with many diseases, caregivers are simply 
unable to cure the problem itself and must resort to masking it. With FMS, however, it is 
even more difficult to alleviate the symptoms, since it is a syndrome with such a wide 
range of symptoms. Regardless, medications can provide partial relief from many of the 
symptoms associated with fibromyalgia, including: pain, anxiety, and insomnia. 
 Analgesics. One such class of medication is, obviously, analgesics. While many 
over the counter drugs (such as acetaminophen, tramadol, and ibuprofen) provide initial 
relief, more powerful analgesics (like morphine or codeine) are periodically administered 
to better control pain. Because some of these more powerful analgesics are potentially 
addictive, they may not be the best solution, however. Patients with fibromyalgia seem to 
be particularly sensitive to codeine, and often experience nausea. In addition, many pain 
medications can cause drowsiness and difficulty concentrating, which mimic one of the 
major symptoms of fibromyalgia anyway, making these drugs less beneficial to an FMS 
patient.  
However, some analgesics do offer hope. For example, one class of analgesics 
which shows a lot of promise is the 5-HT3 receptor antagonists (Seidel & Muller, 2011). 
5-HT3 receptors are ligand-gated ion channels, which when activated by an agonist (such 
as serotonin) have been shown to cause nausea, vomiting, seizures and, more importantly 
for FMS, excitation of the nociceptive neurons (if the receptors are located in the 
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peripheral nervous system). As a result, an antagonist to 5-HT3 can in essence “calm” the 
excited neurons, leading to a decrease in hyperalgesia, or pain sensitivity. Administration 
of 5-HT3 antagonists is currently favored for FMS patients who have physical pain 
(presumably from nociceptors), but no psychological distress. 
 Antidepressants and anti-anxiety medications. Other classes of drugs often 
prescribed to FMS patients are antidepressants and anti-anxiety medications, which help 
with the more psychological aspects of fibromyalgia. As for the antidepressants, many 
classes of drugs seem to have positive results, although some are more beneficial than 
others. One class that seems to be useful is serotonin reuptake inhibitors, such as 
duloxetine and venlafaxine, usually prescribed for major depressive disorder (MDD) and 
general anxiety disorder (GAD).  
In addition to general serotonin reuptake inhibitors, specific serotonin reuptake 
inhibitors (which exclusively prevent the degradation of serotonin) may be tried, such as: 
fluoxetine, paroxetine, and citalopram. Interestingly, although these drugs tend to 
produce a weaker effect, they often have a higher tolerability profile, meaning fewer 
patients with FMS experience adverse effects, such as allergic reactions, nausea, or other 
side effects, when they take these drugs (Dharmshaktu, Tayal, & Kalra, 2012).  
Simply administering serotonin directly has also shown to produce some positive 
effects on depression and insomnia (Juhl, 1998). Anti-anxiety medications, such as 
Klonopin, can also help by reducing restlessness (especially at night) and by activating 
pain inhibitors in the body to facilitate sleep. 
Non-steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are sometimes offered by doctors in lieu of analgesics, since inflammation has 
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historically been assumed to play a major role in the pain. However, these often produce 
minimal results, which is why many caregivers no longer believe that fibromyalgia is an 
inflammatory disease. (The ineffectiveness of NSAIDs does at least offer researchers a 
clue as to the origins of fibromyalgia, and indicates that this disease likely does not stem 
from a purely musculoskeletal derangement). 
Hypnotic drugs.  Since many FMS patients report experiencing non-restorative 
sleep and since many of the symptoms found in FMS are considerably exacerbated by a 
lack of deep sleep, an obvious answer would be to administer sleeping pills. However, 
many sedative drugs have proved ineffective in providing quality sleep. This could be 
due to a decrease in what are called “sleep spindles” in patients with FMS (Landis, Lentz, 
Rothermel, Buchwald, & Shaver, 2004). When an individual is asleep, disruptions are 
typically mitigated by short periods of intense brain activity known as sleep spindles, 
which seem to help maintain tranquility, almost as though the brain is choosing not to 
wake up. This could explain why simply putting patients to sleep seems ineffective at 
providing quality rest, since the pills don’t necessarily cause a deeper sleep. As of yet, 
researchers have not discovered what causes sleep spindles, or why some people tend to 
have more than others, and are examining drugs that may boost their frequency. 
Anticonvulsant drugs. Two of the most commonly prescribed medications for 
fibromyalgia are pregabalin and gabapentin. However, these two drugs are classified as 
antiepileptic drugs, and are administered predominantly to epileptics. Some research 
suggests that both seem to be relatively effective, although they do have significant 
adverse effects, including dizziness, somnolence and dry mouth (Tzellos et al., 2010). 
Regardless, pregabalin is the better known drug and seems to be safe (Straube, Derry, 
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Moore, & McQuay, 2010), making it the drug of choice. Researchers are beginning to 
suspect that antiepileptic drugs (AEDs) may act by binding to the alpha2-delta subunits 
of a voltage gated calcium ion channel (Weissmann, Di Guilmi, Urbano, & Uchitel, 
2013). This is relevant to FMS because these drugs, which reduce epileptic neuronal 
hyperexcitability as well as neuropathic pain, may have a common pathway (possibly in 
the Ca2+ ion channel) (Bialer, 2012). 
Lifestyle Changes 
In addition to medications, other simple treatment plans, like the pharmaceuticals, 
only reduce the severity of the symptoms. Also, there is disagreement among those with 
fibromyalgia as to which of the changes have the greatest impact. Regardless, many FMS 
patients attest to the value of lifestyle habits in reducing symptoms, even though these 
dramatic changes are often the most difficult for the FMS patient to continue to make. 
Dietary changes. One of the easiest changes in lifestyle that can be made by an 
FMS patient is an alteration in his or her diet. However, these recommendations can 
change dramatically from individual to individual. For example, many women find that 
chewing ice helps, while others find relief with a specific drink, such as a Diet Coke or 
(rarely) coffee. Since the effects of a food or drink vary considerably, it seems plausible 
that these may function better in reducing stress than by producing a specific 
physiological effect. 
Some dietary changes seem to have value for other reasons as well. For example, 
a study conducted in 2000 demonstrated a strong correlation between a vegan diet and an 
improvement in fibromyalgia symptoms, including reduced joint stiffness, higher quality 
of sleep, and less pain (measured with both a general health questionnaire and a 
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rheumatologist’s questionnaire) (Kaartinen et al., 2000). Other rheumatoid patients given 
a vegan diet, specifically those rich in antioxidants, lactobacilli, and fiber, also 
experienced significant reductions in their pain (Hanninen et al., 2000).  
Two other diet studies which omit specific food groups seem to make an impact. 
In the first, test subjects participated in a modified elimination diet, eating predominantly 
rice protein power and consuming a higher amount of phytonutrient-rich medical food. 
These FMS patients scored better in many pain and health questionnaires, and even 
seemed to have higher pain tolerance for up to five tender points (Lamb et al., 2011).  
A second study reported a few cases (which do seem to be rare exceptions) in 
which patients actually seemed to suffer from an excess of aspartame in their diets. By 
removing aspartame from the diets of these patients (many of whom had been taking 
aspartame supplements), the chronic pain disappeared almost entirely, even after years of 
pain. The pain would then reappear with the reintroduction of aspartame into the patients’ 
diets (Ciappuccini, Ansemant, Maillefert, Tavernier, & Ornetti, 2010). Although these 
cases appear unusual, the removal of aspartame is an easy treatment for those whom it 
affects.  
Exercise. Despite the fact that vegan diets do seem to play a role in pain 
management for FMS patients, more recent studies suggest that these benefits may occur 
because these diets induce weight loss. One study in particular demonstrated a strong 
correlation between BMI and the number of pressure points a FMS patient has, as well as 
a connection between total levels of cholesterol and triglycerides and pain experienced by 
those with fibromyalgia (Cordero et al., 2013).  
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In addition, other exercises have been shown to alleviate both immediate and 
long-term pain. One specific exercise which seems to be beneficial is swimming. A study 
performed in 2012 demonstrated that low intensity swimming in warm water led to an 
immediate decrease in the pain experienced by participants. It is interesting to note that 
this seemed to have a greater effect on older women and on those with greater pain 
(Segura-Jimenez et al., 2012). Other review studies have also noticed a trend that both 
aquatic exercise and balneotherapy (that is, bathing in warm water or water massages, 
etc.) assist in minimizing pains associated with FMS (Verhagen, Cardoso, & Bierma-
Zeinstra, 2012). 
However, not all of the benefits of exercise are entirely physical. Many studies 
have demonstrated that long term exercise and stretching provide psychological stability 
and health (Sanudo, Galiano, Carrasco, de Hoyo, & McVeigh, 2011). In large part, this 
could be the result of an interesting finding that has been clearly demonstrated over the 
past decade: exercise increases brain-derived neurotrophic factor concentrations (Johnson 
& Mitchell, 2003; M. C. Lee et al., 2013; Oliff, Berchtold, Isackson, & Cotman, 1998). 
As previously mentioned, BDNF may play a role in some of the psychological factors 
associated with FMS. As a result, an increase in exercise could clearly lead to a better 
mindset. 
An additional study which may have implications for FMS suggests that exercise 
increases the concentrations in the brain of both vascular endothelial growth factor 
(VEGF) and insulin-like growth factor type 1, as well as increased connectivity between 
the bilateral hippocampus and the bilateral middle temporal gyrus, demonstrating that 
exercise does in fact alter the brain (Voss et al., 2013). The hippocampus and middle 
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temporal gyrus, both parts of the temporal lobe, seem to play a role in emotional control 
and linguistic comprehension, among other things. This could help explain why exercise 
can have such positive effects on FMS patients (although exercise tends to help even 
healthy individuals considerably).  
Sleep pattern management. Perhaps one of the biggest factors, however, seems 
to be getting enough sleep. Although, as noted previously, medications are insufficient to 
consistently and effectively provide restful sleep, some patients with FMS are able to 
enhance their own sleep quality. Others with FMS have reported sleeping more restfully 
by changing their environment before going to bed (that is, turning off all lights, making 
sure there will be no noises, etc.). If patients with FMS also spend time thinking about 
positive things before going to bed, anxiety may be reduced, leading to more restorative 
sleep. 
Alternative Treatment 
Stress reduction. A major factor in the treatment of fibromyalgia is helping its 
victims learn how to manage stress. There is a plethora of techniques for managing stress, 
and different victims of FMS will advocate different techniques. Perhaps one of the most 
popular techniques is receiving muscle massages, which has little research supporting its 
efficacy, but is commonly recommended by those with FMS (Field et al., 2002). 
Another technique for reducing stress (although often less frequently supported by 
medical practitioners) is meditation. Despite the negative connotations often associated 
with meditation due to its religious aspects, several studies have demonstrated an 
improvement in pain experienced by those with FMS who practice various forms of 
meditation (Liu et al., 2012; Schmidt et al., 2011). 
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Conclusion 
Summary 
Fibromyalgia syndrome is an increasingly well-known condition. However, many 
aspects of this condition remain shrouded in mystery. While medical professionals have 
developed lists of common symptoms, or associated diseases, and have established a 
standardized diagnostic procedure for fibromyalgia, researchers have yet to determine 
what actually causes this condition, or even all the abnormalities in the body which are 
associated with FMS. However, certain pathophysiological tendencies have been 
established and many palliative treatments have been considered and tested. 
Discussion 
Traditionally, rheumatologists have been the physicians most often responsible 
for diagnosing and treating fibromyalgia syndrome, since they are most familiar with the 
frequently associated joint and muscle conditions. However, a closer look at the 
pathophysiology behind FMS, as well as the treatments which seem to be most effective, 
indicates that this condition is predominantly pathoneurological in nature, whether in 
chemical imbalances (such as serotonin or BDNF) or in hyperexcitable sensory neurons. 
In light of these findings, neurologists rather than rheumatologists may be better 
equipped to take the lead in research and new drug development.
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